Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To determine mechanisms by which pioglitazone and metformin effect hepatic and extra-hepatic insulin action. RESEARCH DESIGN AND METHODS—Thirty-one subjects with type 2 diabetes were randomly assigned to pioglitazone (45 mg) or metformin (2,000 mg) for 4 months. RESULTS—Glucose was clamped before and after therapy at ∼5 mmol/l, insulin raised to ∼180 pmol/l, C-peptide suppressed with somatostatin, glucagon replaced at ∼75 pg/ml, and glycerol maintained at ∼200 mmol/l to ensure comparable and equal portal concentrations on all occasions. Insulin-induced stimulation of glucose disappearance did not differ before and after treatment with either pioglitazone (23 ± 3 vs. 24 ± 2 μmol · kg−1 · min−1) or metformin (22 ± 2 vs. 24 ± 3 μmol · kg−1 · min−1). In contrast, pioglitazone enhanced (P < 0.01) insulin-induced suppression of both glucose production (6.0 ± 1.0 vs. 0.2 ± 1.6 μmol · kg−1 · min−1) and gluconeogenesis (n = 11; 4.5 ± 0.9 vs. 0.8 ± 1.2 μmol · kg−1 · min−1). Metformin did not alter either suppression of glucose production (5.8 ± 1.0 vs. 5.0 ± 0.8 μmol · kg−1 · min−1) or gluconeogenesis (n = 9; 3.7 ± 0.8 vs. 2.6 ± 0.7 μmol · kg−1 · min−1). Insulin-induced suppression of free fatty acids was greater (P < 0.05) after treatment with pioglitazone (0.14 ± 0.03 vs. 0.06 ± 0.01 mmol/l) but unchanged with metformin (0.12 ± 0.03 vs. 0.15 ± 0.07 mmol/l). CONCLUSIONS—Thus, relative to metformin, pioglitazone improves hepatic insulin action in people with type 2 diabetes, partly by enhancing insulin-induced suppression of gluconeogenesis. On the other hand, both drugs have comparable effects on insulin-induced stimulation of glucose uptake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These actions modulate the transcription of genes with favorable effects on insulin sensitivity,13,36 fat distribution,37 plasma glucose,35,38 lipid and protein metabolism,36,38 vascular endothelial function,39 and inflammation.35,40”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [36]
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 2×
“Previous studies have shown that thiazolidinediones and metformin inhibit multiple enzymes in the gluconeogenic pathway and when compared to placebo, lower gluconeogenesis in humans (9,10,12-15,43).”
BackgroundResult(1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-3-486_3 · Cited by 2,056
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“The relative ability of these agents to modulate hepatic and extra-hepatic insulin action is uncertain because most studies have compared the effects of a thiazolidinedione or metformin with that observed during treatment with placebo (14,19,21,26–31) or before treatment (13,15,16,18) rather than to one another.”
BackgroundKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Self-citationFryer, L. G. D., Parbu-Patel, A., & Carling, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202489200 · Cited by 1,029
Measurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Dose-response characteristics for effects of insulin on production and utilization of glucose in man
Rizza, R. A., Mandarino, L. J., & Gerich, J. E. (1981) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1981.240.6.e630 · Cited by 703
Self-citation
Research works printed but not linked: 1
- Buse JB, Polonsky KS, Burant CF: Chapter 29: Type 2 Diabetes Mellitus. In Larsen:Williams Textbook of Endocrinology, 10th ed. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, Eds. Philadelphia, PA, Saunders,2003, p.1427–1482
Cited by
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400
Packer, M. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007197 · Cited by 176
Iron, ferroptosis, and ischemic stroke
Guo, J., Tuo, Q., & Lei, P. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15807 · Cited by 160
Kita, Y., Takamura, T., Misu, H., Ota, T., Kurita, S., Takeshita, Y., Uno, M., Matsuzawa-Nagata, N., Kato, K.-I., Ando, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043056 · Cited by 152
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
Hadjadj, S., Rosenstock, J., Meinicke, T., Woerle, H. J., & Broedl, U. C. (2016) · Diabetes Care · doi:10.2337/dc16-0522 · Cited by 115
Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 97
Measurements of Gluconeogenesis and Glycogenolysis: A Methodological Review
Chung, S. T., Chacko, S. K., Sunehag, A. L., & Haymond, M. W. (2015) · Diabetes · doi:10.2337/db15-0640 · Cited by 88
Khattab, M. A., Emad, M., Abdelaleem, A., Eslam, M., Atef, R., Shaker, Y., & Hamdy, L. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02171.x · Cited by 92
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 94
Linden, M. A., Fletcher, J. A., Morris, E. M., Meers, G. M., Kearney, M. L., Crissey, J. M., Laughlin, M. H., Booth, F. W., Sowers, J. R., Ibdah, J. A., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00427.2013 · Cited by 81
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin
Overbeck, K., Genné, D., Golay, A., & Negro, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.03.033 · Cited by 80
Matafome, P. N., Louro, T. M., Rodrigues, L., Crisóstomo, J., Nunes, E., Amaral, C. P., Monteiro, P. F., Cipriano, A., & Seiça, R. M. F. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1157 · Cited by 81
Gluconeogenesis Flux in Metabolic Disease
Shah, A. M., & Wondisford, F. E. (2023) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061121-091507 · Cited by 62
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Edgerton, D. (2009) · Frontiers in Bioscience · doi:10.2741/3301 · Cited by 54
Das, S. K., Chu, W. S., Mondal, A. K., Sharma, N., Kern, P. A., Rasouli, N., & Elbein, S. C. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90355.2008 · Cited by 59
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Gudbjörnsdottir, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 46
Linden, M. A., Lopez, K. T., Fletcher, J. A., Morris, E. M., Meers, G. M.-E., Siddique, S., Laughlin, M. H., Sowers, J. R., Thyfault, J. P., Ibdah, J. A., et al. (2015) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2015-0236 · Cited by 46
Cuthbertson, J., Patterson, S., O'Harte, F. P. M., & Bell, P. M. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02748.x · Cited by 50
Felts, A. S., Siegel, B. S., Young, S. M., Moth, C. W., Lybrand, T. P., Dannenberg, A. J., Marnett, L. J., & Subbaramaiah, K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700969c · Cited by 41
Packer, M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107647 · Cited by 43
Gastaldelli, A., Casolaro, A., Ciociaro, D., Frascerra, S., Nannipieri, M., Buzzigoli, E., & Ferrannini, E. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90960.2008 · Cited by 36
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs
Zhao, Y. D., Zhao, W., Wang, H., Zhao, Y., Bu, H., & Takahashi, H. (2022) · Medicine · doi:10.1097/md.0000000000031508 · Cited by 35
Plaisance, E. P., Grandjean, P. W., Judd, R. L., Jones, K. W., & Taylor, K. J. (2009) · Metabolism · doi:10.1016/j.metabol.2009.04.038 · Cited by 40
Platelets and endothelial dysfunction in gestational diabetes mellitus
Valero, P., Cornejo, M., Fuentes, G., Wehinger, S., Toledo, F., van der Beek, E. M., Sobrevía, L., & Moore‐Carrasco, R. (2023) · Acta Physiologica · doi:10.1111/apha.13940 · Cited by 36
Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure
Perez, D. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115783 · Cited by 33
Cacoub, P., Carrat, F., Bédossa, P., Lambert, J., Pénaranda, G., Pol, S., & Halfon, P. (2009) · Antiviral Therapy · doi:10.3851/imp1298 · Cited by 37
Hardy, T. A., Abu-Raddad, E., Pørksen, N. K., & Gaetano, A. D. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00421.2011 · Cited by 31
Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Gad, M. Z., Ehssan, N. A., Ghiet, M. H., & Wahman, L. F. (2010) · PubMed · Cited by 28
Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes
Ewan, R. P. (2009) · Frontiers in bioscience · doi:10.2741/3532 · Cited by 23
Pavlov, T. S., Levchenko, V., Ilatovskaya, D. V., Li, H., Palygin, O., Pastor‐Soler, N. M., Hallows, K. R., & Staruschenko, A. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00227 · Cited by 24
Roden, M., Mariz, S., Brazzale, A. R., & Pacini, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02040.x · Cited by 19
Zanchi, A., Tappy, L., Lê, K., Bortolotti, M., Theumann, N. H., Halabi, G., Gauthier, T., Mathieu, C., Tremblay, S., Bertrand, P. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109134 · Cited by 19
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes
Basu, R., Basu, A., Chandramouli, V., Norby, B., Dicke, B. A., Shah, P. J., Cohen, O., Landau, B. R., & Rizza, R. A. (2008) · Diabetologia · doi:10.1007/s00125-008-1138-1 · Cited by 17
Self-citationA Review on Metformin: Clinical Significance and Side Effects
Mazumder, A., & Ashini, S. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.01070 · Cited by 28
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes
Phielix, E., Brehm, A., Bernroider, E., Krššák, M., Anderwald, C. H., Krebs, M., Schmid, A. I., Nowotny, P., & Roden, M. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12112 · Cited by 16
Huang, F., Zeng, Z., Zhang, W., Yan, Z., Chen, J., Yu, L., Yang, Q., Li, Y., Yu, H., Chen, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113542 · Cited by 15
Cravalho, C. K. L., Meyers, A. G., Mabundo, L. S., Courville, A. B., Yang, S. B., Cai, H., Dai, Y., Walter, M. F., Walter, P. J., Sharma, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05236-y · Cited by 18
Thermogenesis and Related Metabolic Targets in Anti-Diabetic Therapy
Arch, J. R. S. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_10 · Cited by 15
DIETSCHE, K. B., Magge, S. N., Dixon, S. A., Davis, F., Krenek, A. M., Chowdhury, A., Mabundo, L. S., Stagliano, M. S., Courville, A. B., Yang, S. B., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad669 · Cited by 15
Basu, R., Chandramouli, V., Dicke, B. A., Landau, B. R., & Rizza, R. A. (2008) · Diabetes · doi:10.2337/db08-0195 · Cited by 12
Self-citationMetformin—mechanisms of its glycemia-reducing effect
Drewe, J., Foretz, M., & Krähenbühl, S. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100106 · Cited by 19
Shojaei‐Zarghani, S., Abbaszadeh, S., Alizadeh, M., Rameshrad, M., Garjani, A., & Soraya, H. (2018) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2018.012 · Cited by 11
Kang, S. B., Kim, H. M., Kim, H. J., Seok, H., Huh, J. H., Lee, B., Kang, E. S., Lee, H. C., & Soo, B. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0167 · Cited by 7
Bonet, J., YADAV, Y. R., Miles, J. M., Basu, A., Cobelli, C., Basu, R., & Man, C. D. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00091.2023 · Cited by 7
Self-citationKim, T., Lee, J.-H., Chae, Y., Jung, I.-H., & Kim, M.-K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.033 · Cited by 6
Thabit, H., Kumareswaran, K., Haidar, A., Leelarathna, L., Caldwell, K., Elleri, D., Allen, J. M., Nodale, M., Wilinska, M. E., Jackson, N. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4519 · Cited by 7
Gad, M. Z., Ehssan, N. A., Ghiet, M. H., & Wahman, L. F. (2019) · International Journal of Diabetes and Metabolism · doi:10.1159/000497703 · Cited by 8
Kutoh, E., Kuto, A. N., Wada, A., Kurihara, R., & Kojima, R. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14914 · Cited by 4
Stern, J. H., Arriaga, Y. E., Gupta, A., Verma, U. N., Karri, S., Syed, S. K., Khosama, L., Mansour, J. C., Meyer, J., Scherer, P. E., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001208 · Cited by 5
Rakhsha, S. S., Shahinfar, H., Ebrahimi-Mousavi, S., Kosari, A., Aali, Y., Mirzababaei, A., Hosseini, S. A., Jadidi, P., Shafiee, G., Mansourzadeh, M. J., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70957 · Cited by 3
Zaki, H. A., Iftikhar, H., Shallik, N. A., Shaban, E. E., Al-Marri, N. D. R., Bashir, I., Elhadad, A., Zoghlami, F., & Abdalrubb, A. (2023) · Cureus · doi:10.7759/cureus.39445 · Cited by 6
Selim, S., Nabi, M.-U., Saifuddin, M., Hannan, M. A., Bakar, M. A., Talukder, S. K., Kamrul-Hasan, A. B. M., Amin, M. N., Hoque, M. A., Rahman, M. S., et al. (2021) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2021.118012 · Cited by 2
Which is the eligible patient to be treated with pioglitazone? The expert view
Avogaro, A., Federici, M., Betteridge, J. D., Bonadonna, R. C., Campbell, I. W., Schernthaner, G., Staels, B., Farinaro, E., & Crepaldi, G. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346725 · Cited by 2
Agnes, C. (2022) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2022.46.007345 · Cited by 2
LEPTIN RESISTANCE AND TYPE 2 DIABETES
Oleshchuk, O., & Лой, Г. Я. (2017) · International Journal of Medicine and Medical Research · doi:10.11603/ijmmr.2413-6077.2017.1.7563 · Cited by 2
Schinner, S. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79332-1
Metabolic effects of dipeptyl peptidase 4 inhibitor in type 2 diabetes
Macauley, M. (2016)
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32830c6b8e
Current literature in diabetes
(2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.899
Ahmed, S., McCollin, S. P., Martí-Carvajal, A. J., Akus, M., Baron, D. W., Razzaq, S. A., Scudder, P. N., Honigsberg, E. J., Nasir, S., Peng, K., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016380
Metadata
- Authors
- Basu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., & Rizza, R. A.
- Affiliations
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Case Western Reserve University (US)
- Sheba Medical Center (IL)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-01-01
- Volume
- 57
- Issue
- 1
- Pages
- 24-31
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2156803989
- Cited by
- 63
- References
- 49
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 6 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- U.S. Public Health Service
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-14507, DK 29953)
- National Center for Research Resources (RR-00585, U 54RR 24150-1, M01RR000585)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, metformin, type 2 diabetes, insulin action, hepatic insulin action, glucose production, gluconeogenesis, free fatty acids, insulin sensitivity, thiazolidinediones, glucose clamp, C-peptide, glucagon, glycerol infusion, insulin resistance, antidiabetic drugs
- MeSH terms
- Pioglitazone, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Diet, Diabetic, Double-Blind Method, Drug Administration Schedule, Fatty Acids, Nonesterified, Female, Glucagon, Gluconeogenesis, Glycerol, Humans, Hypoglycemic Agents, Infusions, Intravenous, Insulin, Kinetics, Liver, Male, Metformin, Middle Aged, Placebos, Glucose Clamp Technique, Body Mass Index, Thiazolidinediones, Glycogenolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.